Q3 is a defining momentCZO's merger with AEZS is expected to close in Q3(June 3).
Top line results from AEZS's pediatric clinical trial are expected in Q3.
100L PGX scale-up commissioning, the decision point for mass industrialization, is expected in Q3.
50L PGX scale-up was said "almost complete" last news release and previously was said to provide materials for potential partners to evaluate. A filing with Health Canada could be made for potential approval of the first PGX product.
In Q3 the company should complete the single escalating dose portion of its avenanthramide clinical study. PGX-fibrosis was said to require a short study previously and a comprehensive package has been sent for publication to the journal Biomaterials.